New York Times Company Continues to Thrive in the Media Industry\n\nThe New York Times Company has been a leading force in the media industry for over a century, and its success shows no signs of slowing down. The challenges faced by the industry in recent years, the company has continued to thrive and adapt, solidifying its position as a resilient and attractive choice for those seeking news and information.\n\nThe company’s success can be attributed to its strong fundamentals and strategic initiatives. Its commitment to quality journalism and unbiased reporting has earned it a loyal readership and a reputation for credibility. Its digital transformation has also played a significant role, with a growing number of subscribers choosing to access its content online. \n\nIn addition to its strong fundamentals, the New York Times Company has also seen impressive results through its strategic initiatives. Its focus on diversifying revenue streams and expanding its digital presence has paid off, with digital advertising and subscriptions seeing significant growth. \n\nThe company’s resilience and adaptability have not gone unnoticed, with many industry experts praising its ability to navigate the ever-changing media landscape. Its strategic initiatives continue to yield impressive results, further solidifying its position as a leader in the industry. Its commitment to quality journalism and digital transformation have not only helped it weather the storm, but also attract readers and advertisers in a highly competitive market.\n\nIn a the New York Times Company’s success in the media industry is a testament to its strong fundamentals and strategic initiatives.

Cassava Sciences, Inc. Announces Warrant Distribution to Shareholders\n\nCassava Sciences, Inc. (Nasdaq:SAVA) has announced a pro rata dividend distribution of warrants to holders of the Company's common stock as of December 22, 2023. The warrants will be distributed to shareholders free of charge on or about January 3, 2024.\n\nThe warrants, which are expected to list and trade on Nasdaq under the ticker SAVAW, will entitle the holder to purchase one share of common stock at an initial exercise price of $33.00 per share. This distribution is part of the Company's efforts to raise capital for its ongoing Phase 3 clinical development of oral simufilam in people with Alzheimer's disease.\n\nDetails of Warrant Distribution\n\nShareholders will receive 4 warrants for each 10 shares of common stock held as of the Record Date, rounded down to the nearest whole number for any fractional warrant. For example, a shareholder who owns 1,000 shares of Cassava Sciences will receive 400 warrants. After the Distribution Date, warrant holders may cash-exercise their warrants or sell them on the open market.\n\nThe warrants will expire on November 15, 2024, at 5:00 p.m. New York City time, unless redeemed by the Company before that date. The Company will have the option to redeem the warrants on or after April 15, 2024, upon 20 calendar days' notice.\n\nDetails of Bonus Share Program\n\nIn addition to the warrants, shareholders will also receive a Bonus Share Fraction, entitling them to an additional 0.5 of a share of common stock for each warrant exercised without payment of any additional exercise price. The right to receive the Bonus Share Fraction will expire on the earlier of (i) the first business day following the last day of the first 30 consecutive trading day period in which the daily volume weighted average price (VWAP) of the shares of common stock has been at least equal to a specified price, initially $26.40 per share, for at least 20 trading days and (ii) the Bonus Share Expiration Date.\n\nCassava Sciences, Inc. Has announced a warrant distribution to its shareholders, allowing them to participate in the Company's process of raising capital. The warrants will be listed and traded on Nasdaq, separate from the Company's common stock. Shareholders may exercise their warrants or sell them on the open market.